KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment: 2009-2025

  • Biomarin Pharmaceutical's Asset Writedowns and Impairment was N/A to $3.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $19.9 million for FY2024, which is 48.48% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Asset Writedowns and Impairment stood at $3.0 million for Q1 2025, which was down 47.81% from $5.7 million recorded in Q3 2024.
  • Biomarin Pharmaceutical's 5-year Asset Writedowns and Impairment high stood at $26.0 million for Q4 2023, and its period low was $3.0 million during Q1 2025.
  • Its 3-year average for Asset Writedowns and Impairment is $12.3 million, with a median of $12.7 million in 2023.